Description
Liraglutide
Liraglutide shares 97% sequence similarity with natural GLP-1 but includes alterations that prolong its activity in the body. It helps regulate blood sugar by delaying stomach emptying, enhancing insulin release, and reducing glucagon secretion. Additionally, it influences areas of the brain involved in appetite control, leading to decreased hunger.
Also known as: Victoza, Saxenda
A GLP-1 receptor agonist approved by the FDA for managing type 2 diabetes and long-term weight control. It served as the precursor to semaglutide and is administered daily.
•Status: FDA-approved. Evidence level: FDA-approved.
•Standard dosage: 1.8–3 mg per day, delivered once daily via subcutaneous injection.
•Studied for: Weight management, blood sugar regulation, and reducing appetite.
•Status: FDA-approved. Evidence level: FDA-approved.
•Standard dosage: 1.8–3 mg per day, delivered once daily via subcutaneous injection.
•Studied for: Weight management, blood sugar regulation, and reducing appetite.
Reviews
There are no reviews yet.